BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Poised to Spearhead Advancements in Battle Against Diseases, Harness Cutting-Edge AI Technology

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, recently announced a definitive agreement to combine with the advanced AI company GEDiCube International Ltd, rebranding as Renovaro AI. “The company has also announced the addition of three new members to its board of directors – Avram Miller, Leni Boeren and Ruud Hendriks. Leni Boeren brings a 40-year career in the financial sector, with banking roles at Paribas and Rabobank… Ruud Hendriks brings over 35 years of experience in asset management, having held senior roles at some of the most established financial institutions… Avram Miller is an American businessperson, corporate venture capitalist, scientist, and technologist who served as vice president of business development for Intel Corporation and co-founded Intel Capital, a division of Intel Corporation set up to manage corporate venture capital, global investment, mergers and acquisitions,” reads a recent article. “I look forward to supporting the company in unlocking the vast potential of the two companies. Together, we are committed to spearheading advancements in the battle against cancer and other diseases, harnessing cutting-edge AI technology and pioneering biotherapeutics,” Boeren is quoted as saying.

To view the full article, visit https://ibn.fm/P378d

About Renovaro BioSciences Inc.

Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN